Zacks: Analysts Expect Cellectis SA (CLLS) Will Announce Quarterly Sales of $9.43 Million

Share on StockTwits

Equities analysts expect that Cellectis SA (NASDAQ:CLLS) will announce $9.43 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Cellectis’ earnings, with the highest sales estimate coming in at $10.69 million and the lowest estimate coming in at $7.60 million. Cellectis reported sales of $8.96 million during the same quarter last year, which indicates a positive year over year growth rate of 5.2%. The firm is expected to report its next quarterly earnings report on Wednesday, August 1st.

According to Zacks, analysts expect that Cellectis will report full-year sales of $36.10 million for the current fiscal year, with estimates ranging from $31.30 million to $41.98 million. For the next fiscal year, analysts expect that the firm will report sales of $47.77 million per share, with estimates ranging from $32.00 million to $77.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Cellectis.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Monday, May 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.01). Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%. The firm had revenue of $8.07 million for the quarter, compared to the consensus estimate of $9.53 million.

Several equities analysts have weighed in on CLLS shares. Zacks Investment Research cut shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. BidaskClub upgraded shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. Nomura lifted their price objective on shares of Cellectis to $73.00 and gave the stock a “buy” rating in a research report on Wednesday, March 14th. Guggenheim started coverage on shares of Cellectis in a research report on Friday, March 16th. They set a “neutral” rating on the stock. Finally, ValuEngine upgraded shares of Cellectis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Cellectis has an average rating of “Hold” and an average price target of $42.00.

Large investors have recently modified their holdings of the business. Perceptive Advisors LLC bought a new position in Cellectis during the fourth quarter valued at about $10,203,000. Nexthera Capital LP purchased a new stake in Cellectis in the first quarter valued at $10,485,000. BlackRock Inc. purchased a new stake in Cellectis in the fourth quarter valued at $4,422,000. Millennium Management LLC raised its position in Cellectis by 1,356.2% in the fourth quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock valued at $3,040,000 after purchasing an additional 97,128 shares during the period. Finally, Bain Capital Public Equity Management LLC purchased a new stake in Cellectis in the fourth quarter valued at $2,848,000. 16.76% of the stock is owned by institutional investors.

NASDAQ CLLS opened at $29.95 on Wednesday. Cellectis has a twelve month low of $21.25 and a twelve month high of $38.85. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -10.77 and a beta of 1.88.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with's FREE daily email newsletter.

Leave a Reply